Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

July 9, 2019

Limited Cancer-Related Fatigue Regression Highlights Need for Intervention

Author(s):

Kristie L. Kahl
Conference|ASCO Annual Meeting

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention, according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

“My experience in managing patients who experience cancer-related fatigue is that it's often one of the most burdensome symptoms and it impacts many aspects of their lives,” study author Hanneke Poort, a psychologist and post-doctoral research fellow in the Department of Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute in Boston, said in an interview with CURE.

“Patients often don't know that this is something that can be addressed, so they either do not report it to their doctors or they feel like this is something they just have to live with,” she added. “But fortunately, there are interventions that we can use to reduce this debilitating symptom.”

In a secondary analysis of a prospective cohort study, the ROGY Care trial, she and colleagues aimed to identify clinically-distinct subgroups of patients with fatigue over time and the medical and psychological predictors of clinically significant fatigue one year after diagnosis.

“There has been a lot of research looking into cancer-related fatigue, but not many studies looked into the course of fatigue over time, and whether or not fatigue resolves without an intervention,” Poort explained. “The studies that have been performed have mostly been done in patients with other cancer types. That was one of the main reasons for us to do this study.”

Fatigue, depression and anxiety were assessed after surgery, six months after surgery and 12 months after surgery with the 10-item Fatigue Assessment Scale and the Hospital Anxiety and Depression Scale.

In total, 112 women with newly-diagnosed ovarian cancer and 200 women with newly-diagnosed endometrial cancer were included in the study analysis. Women were a median age of 66 years.

At baseline, 49% of the 312 participants reported having clinically significant fatigue. One year later, 42% had persistent fatigue.

In that year, the majority reported with moderate fatigue (45%), followed by no fatigue (41%). Only 15% reported severe symptoms.

Those with two or more comorbid conditions, clinically significant fatigue at baseline and depressive symptoms at baseline appeared to be more likely to report experiencing clinically significant fatigue at one year.

However, Poort noted, there are interventions focusing on the psychological factors that have been shown to be helpful in reducing fatigue, such as exercise or cognitive behavioral therapy.

“Patients should takeaway that fatigue is a very common symptom. You're not the only one experiencing this debilitating symptom,” she said. “Importantly, without intervention, it's not likely to get better, but there are ways that we can help you deal with this fatigue and hopefully improve your quality of life.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of woman with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Related Content
Advertisement
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
August 2nd 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
cancer horizons logo: a white microphone on a navy blue background
August 2nd 2025

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
August 2nd 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
cancer horizons image for podcast
August 2nd 2025

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 2nd 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Image of kidney.
August 2nd 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
Related Content
Advertisement
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
August 2nd 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
cancer horizons logo: a white microphone on a navy blue background
August 2nd 2025

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Adding casdatifan to Cabometyx showed encouraging activity and in previously treated ccRCC: © stock.adobe.com.
August 2nd 2025

Welireg Plus Cabometyx Shows Tumor Control in Kidney Cancer Trial

Tim Cortese
Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.
cancer horizons image for podcast
August 2nd 2025

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer: © stock.adobe.com
August 2nd 2025

Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes

Tim Cortese
Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.
Image of kidney.
August 2nd 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.